European Journal of Molecular & Clinical Medicine

Abstract

The central nervous system (CNS) is the control centre of the body. It integrates information received to coordinate and influence the body's activity. Central nervous system disorders, such as neuralgia, dementia, epilepsy, anxiety, and insomnia, profoundly debilitate human behavioral, social, and cognitive functions (1,2). Besides accounting for 39% of deaths worldwide, CNS disorders also result generally in poor quality of life (1,3). Moreover, CNS disorders place a severe challenge on healthcare systems. An extensive study by the European Brain Council estimated the total cost of brain disorders across Europe at 798 billion pounds in 2010 (4). Despite the significant impact of CNS disorders on individuals and society, new drug development in this field of medicine remains limited. Treatments for CNS disorders, such as depression and schizophrenia, are still largely based on substances identified in the 1950s (5). Therefore, novel and active chemical substances for the treatment of CNS disorders are to be discovered.